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The mammalian target of rapamycin (mTOR)
signaling network is central to the regulation of
cell growth in response to both growth factors
and nutrients. We developed a high-through-
put, cell-based assay to identify small-molecule
modulators of the mTOR signaling network.
One such compound, which we name quinosta-
tin, potently inhibits this network by directly
targeting the lipid-kinase activity of the catalytic
subunits of class Ia PI3Ks. This study illustrates
the power of unbiased, phenotypic screening
as a means for illuminating cell circuitry, and
resulted in the identification of a chemotype
for selective inhibition of the class Ia PI3Ks.
INTRODUCTION
The mammalian target of rapamycin (mTOR) signaling
network receives inputs from both small molecules and ex-
tracellular proteins and plays an important role in regulat-
ing cell growth and metabolism in response to environ-
mental cues [1, 2]. Carbon and nitrogen sources, such as
glucose and glutamine, are primary stimuli of mTOR, yet
the mechanisms by which they stimulate the mTOR path-
way are still unknown. The canonical mTOR pathway
(TSC/Rheb/mTOR/rictor/raptor) is impinged upon indi-
rectly by mitogen signaling, for example, by mitogen-
activated receptor tyrosine kinases (RTKs) such as the
insulin and insulin-like growth factor I (IGF-I) receptors.
Signals mediated by RTKs regulate mTOR signaling pri-
marily through the PI3K/Akt pathway. RTK signaling may
also regulate mTOR, albeit to a lesser extent, through the
mitogen-activated protein kinase (MAPK) pathway involv-
ing ERK and RSK (also known as p90 S6K) [3–5]. It is be-
lieved that signals from these two pathways converge at
the protein complex consisting of TSC1 (hamartin) and
TSC2 (tuberin). TSC2 is the GTPase-activating protein
(GAP) for the Ras-family GTP-binding protein Rheb, which
has been reported to bind directly and to activate the rapa-
mycin-sensitive raptor-mTOR complex. mTOR is also
found in a rapamycin-insensitive rictor-mTOR complex,
and this complex has been reported to be responsible for
the phosphorylation of serine473 of Akt [6], the directChemistry & Biology 14,upstream regulator of TSC1/2 in the PI3K/Akt pathway.
The raptor-mTOR complex regulates cell growth and pro-
liferation via the downstream targets ribosomal S6 kinase 1
(p70 S6K1) and eukaryotic translation initiation factor 4E
binding protein 1 (4E-BP1). Cellular energy status is also
believed to regulate mTOR signaling through the TSC1/2
complex. However, nutrient-derived signals might be reg-
ulating mTOR signaling independent of TSC1/2 [7]. In
accord with its critical roles in integrating growth factor,
nutrient, and energy signalings, dysregulation of the
mTOR pathway is associated with certain cancers, cardio-
vascular disease, autoimmunity disorders, and metabolic
disorders.
The study of the mTOR signaling network has relied
extensively on the use of small molecules. Rapamycin en-
abled the discovery and characterization of mTOR [8, 9],
while wortmannin and, more recently, a family of small-
molecule inhibitors of lipid kinases have illuminated
PI3K/Akt signaling [10]. Small molecules that target down-
stream elements of TOR signaling, e.g., uretupamine,
which targets Ure2p, and that either enhance or suppress
the cellular phenotypes of cells treated with rapamycin
have shined a bright light on mTOR circuitry [11–13].
Here, we have extended these studies by developing
a high-throughput, cell-based assay to screen for addi-
tional small-molecule modulators of mTOR signaling. We
report the discovery of quinostatin (named after its quino-
line core structure and its antiproliferative effect), which
was identified from a collection of 20,000 compounds
as a potent modulator of signals that impinge on the S6
protein, whose phosphorylation is under the control of
both PI3K/Akt and mTOR signaling. We show that quino-
statin prevents the phosphorylation of S6 in cells by inhib-
iting the lipid-kinase activity of the class Ia phosphatidyl-
inositol 3-kinase (PI3K). PI3K is a signaling protein of
considerable interest from a therapeutic perspective;
thus, these studies also reveal a completely new, to our
knowledge, type of small-molecule structure (chemotype)
that can serve as a starting point for therapeutic discovery.
RESULTS
Identification of Quinostatin as an Inhibitor
of Cellular S6 Phosphorylation
by Cell-Based Screening
mTOR regulates the activity of the ribosomal protein
kinase p70 S6K, thereby controlling phosphorylation of371–377, April 2007 ª2007 Elsevier Ltd All rights reserved 371
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Kinase Inhibitor through Cell-Based ScreeningFigure 1. Quinostatin Inhibited S6 Phos-
phorylation
(A) The structure of quinostatin.
(B) Immunoblotting showed that the phosphor-
ylation of the S6 and p70 S6K proteins in A549
cells was inhibited by quinostatin. The S6 pro-
tein level was also reduced. The p70 S6K pro-
tein level was not significantly affected. Rapa-
mycin was used as the positive control. QS,
quinostatin; Rap, rapamycin.
(C) Immunodetection showed that the phos-
phorylation of S6 protein in MCF7 cells was
dose-dependently inhibited by quinostatin
treatment. Data presented are means of three
independent experiments with standard errors.
(D) Quinostatin also does-dependently in-
hibited A549 proliferation as measured by Cell-
Titer-Glo. Data presented are means of three
independent experiments with standard errors.the 40S ribosomal protein S6 [14]. Phosphorylation of S6
at serine235/236 is therefore frequently used as readout
for the activity of the mTOR signaling pathway. A high-
throughput cytoblot assay [15] was developed to monitor
the phosphorylation of the S6 protein by immunodetec-
tion. Briefly, A549 lung carcinoma cells in complete
growth media were treated with compounds at a final con-
centration of 10 mg/ml in 384-well assay plates. The cells
were allowed to incubate for 5 hr before S6 phosphory-
lation levels were examined by immunodetection with
a phospho-S6 (serine235/236) primary antibody and an
HRP-conjugated secondary antibody. Approximately
20,000 compounds were screened for their ability to de-
crease the phosphorylation level of S6. The positives
from this primary screen were validated in a secondary cy-
toblot assay by using an a-tubulin primary antibody/HRP-
conjugated secondary antibody detection system. This
assay helped to identify false positives that caused cells
to detach from the assay plates. A number of compounds,
including quinostatin (Figure 1A), were identified as potent
antagonists of S6 phosphorylation. The inhibition of S6
phosphorylation by quinostatin was verified by immuno-
blotting (Figure 1B). The phosphorylation level of p70
S6K, which directly correlates with its kinase activity,
was also reduced. To a lesser extent, the total S6 protein
level was also reduced upon quinostatin treatment. This is
consistent with the observation that mTOR signaling reg-
ulates the translation of a subset of mRNAs that contains
a 50 tract of oligopyrimidine (TOP) [1, 2]. The 50 TOP
mRNAs encode components of the translation apparatus,
such as ribosomal proteins and elongation factors. The to-
tal p70 S6K level was not significantly affected. The effect
of quinostatin proved to be general in all cell lines tested,
including A549, MCF7, HeLa, Jurkat, HCT116, and U2OS.
An IC50 of 2 mM (MCF7, Figure 1C) to 8 mM (A549) was
observed. Consistent with its biochemical effect on S6372 Chemistry & Biology 14, 371–377, April 2007 ª2007 Elseviphosphorylation, quinostatin also inhibited A549 prolif-
eration in a dose-dependent manner (IC50 of 8 mM,
Figure 1D).
Structure-Activity Relationship of Quinostatin
A collection of structural analogs of quinostatin was as-
sembled, and the compounds were tested for their ability
to inhibit S6 phosphorylation (Figure 2). (The compounds
were either purchased from commercial vendors or were
synthesized in house. The protocol for synthesizing the
compounds will be published in due course.) The
40-substituted piperidine appears to be important for qui-
nostatin function: replacing the 40-substituted piperidine
with pyrrolidine, azepane, or unsubstituted piperidine
caused a loss of activity, while polar substitutions at the
40 position of piperidine helped to potentiate the com-
pound. The highest activity was observed when the 40
position was substituted with an amidocarbonyl group
as in quinostatin. It is possible that hydrogen bonds
formed between the 40-amidocarbonyl and amino acids
at the binding site of the target protein help to stabilize
the small-molecule/protein interaction. The p-ethylphenyl
substitution of C3-carbonyl proved not to be essential,
and it can be replaced by an ethoxy without any detrimen-
tal effect on the activity. However, the C3-carbonyl is
critical since replacement of the C3-carbonyl with a cyano
or converting the carbonyl to an oxime abolished the
activity. Interestingly, compound A, a known inhibitor of
EGF receptor [16], did not inhibit S6 phosphorylation.
Quinostatin Targets the PI3K/Akt Pathway
Since the molecular target of quinostatin was unknown,
we set out to characterize the effects of quinostatin
on both PI3K/Akt and MAPK signaling, the two major
pathways responsible for regulating mTOR signaling in
response to growth-factor stimulations.er Ltd All rights reserved
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Kinase Inhibitor through Cell-Based ScreeningFigure 2. Structure/Activity Relationships of Quinostatin
The results are presented as the S6 phosphorylation level in the presence of the test compound (20 mM) as a percentage of that in control incuba-
tions in A549 pS6-cytoblot assays.The S6 protein was phosphorylated under complete
growth media conditions, reflecting the basal activity of
mitogen-activated signaling. This phosphorylation of the
S6 protein in A549 cells was inhibited by wortmannin
treatment (results not shown). Wortmannin covalently
modifies the ATP-binding site of the catalytic subunit of
class Ia PI3Ks (p110) and inhibits the lipid-kinase activity
of the catalytic subunit [17]. Strong inhibition of S6 phos-
phorylation by wortmannin suggests that the PI3K/Akt
pathway regulates mitogen-mediated mTOR signaling un-
der the complete growth media conditions. Similar inhibi-
tion of S6 phosphorylation by wortmannin treatment was
also observed when the cells were stimulated with insulin
(Figure 3). Quinostatin abolished S6 phosphorylation both
in the presence or absence of insulin stimulation. On the
other hand, the MEK1/2 inhibitor U0126 [18] has no effect
on insulin-stimulated S6 phosphorylation. To investigate
whether the MAPK pathway was involved in quinostatinChemistry & Biology 14,function, we also examined the effect of quinostatin on
MAPK signaling. Phorbol 12-myristate 13-acetate (PMA)
is known to activate MAPK signaling by stimulating the
kinase activity of PKC, which, in turn, activates MAPK
signaling through Ras and Raf proteins [3]. Consistent
with the parallel roles of the PI3K/Akt and MAPK pathways
in regulating mTOR signaling [3–5], wortmannin or U0126
alone only partially inhibited S6 phosphorylation caused
by PMA treatment. Simultaneous inhibition of both the
PI3K/Akt and MAPK pathways by wortmannin and
U0126 was required to abolish PMA-stimulated S6 phos-
phorylation. A combination of quinostatin and U0126 also
strongly inhibited PMA-stimulated S6 phosphorylation.
On the other hand, quinostatin alone or in combination
with wortmannin only partially inhibited S6 phosphoryla-
tion caused by PMA treatment. These results suggest
that quinostatin exerts its effect on S6 phosphorylation
through the PI3K/Akt pathway.371–377, April 2007 ª2007 Elsevier Ltd All rights reserved 373
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To investigate quinostatin’s mechanism of action further,
we carried out affinity chromatography purification to
identify the protein target of quinostatin. Specifically, an
analog of quinostatin was prepared by attaching a polyeth-
ylene glycol linker to the C3-carbonyl through an amide
bond (Figure 4A, compound B). This modified compound
was found to be 100-fold less active than quinostatin in the
S6 phosphorylation assay (data not shown). Since substi-
tution at the C3-carbonyl was shown to be inconsequen-
tial to quinostatin’s activity, this dramatic reduction of
potency might be attributed to poor cell permeability
caused by the polyethylene glycol appendage instead of
a disruption of the interactions at the protein binding
site. The affinity reagent was prepared by immobilizing
the polyethylene glycol-modified molecule onto agarose
beads through a second amide bond. In order to isolate
the proteins that interact with quinostatin, MCF7 cell ly-
sate was incubated with the affinity reagent. After the resin
had been extensively washed, the associated proteins
were analyzed by SDS-PAGE. A number of bands were
identified by silver staining. Performing the affinity capture
in the presence of 100 mM quinostatin to compete with the
resin for binding caused a single 85 kD band to disap-
pear, suggesting that it corresponded to a possible target
(Figure 4B). After in-gel trypsin digestion and LC/MS anal-
ysis, the band was found to consist of class Ia PI3K regu-
latory subunits p85a and p85b. This result was indepen-
dently confirmed by immunoblotting with a p85-specific
antibody (Figure 4C). The class Ia PI3K consists of a regu-
latory subunit, p85, and a catalytic subunit, p110 [19]. The
two subunits form a functional heterodimeric complex
through noncovalent interactions. Since staining caused
by nonspecific binding proteins overlapped the region
corresponding to p110, the affinity-purified proteins
were probed for p110 by immunobloting with a p110-spe-
cific antibody. Indeed, the p110 catalytic subunit was also
affinity purified in a manner that was sensitive to the pres-
ence of quinostatin (Figure 4C). The interaction between
Figure 3. Immunoblot of Phospho-S6 in A549 Cells Stimu-
lated with Insulin or PMA
Wortmannin or quinostatin alone was able to inhibit insulin-stimulated
S6 phosphorylation. However, a combination of U0126 and wortman-
nin or quinostatin was required to inhibit PMA-stimulated S6 phos-
phorylation.374 Chemistry & Biology 14, 371–377, April 2007 ª2007 Elsevip85/p110 and the affinity resin was sensitive to the pres-
ence of LY294002, a noncovalent PI3K inhibitor [20] that
targets the ATP-binding site of p110 [21]. In addition, the
affinity resin was also able to pull down a recombinant
p110 from a solution of the purified protein, and this affinity
was sensitive to the presence of quinostatin (Figure 4D).
The affinity between quinostatin and the recombinant
p85a/p110a complex was quantified by using surface
plasma resonance, and a KD of 0.6 mM was observed
at 5C. The effect of quinostatin on the lipid-kinase activity
of the recombinant p85a/p110a complex was tested by
using an in vitro lipid-kinase assay. Quinostatin dose-
dependently inhibited the lipid-kinase activity with an
IC50 of 15 mM (Figure 4E). Quinostatin also inhibited the
lipid-kinase activity of recombinant p110g, an isoform of
p110a, with a slightly lower potency (IC50 of 30 mM).
DISCUSSION
Class Ia PI3Ks exert their physiological functions by cata-
lyzing the phosphorylation of phosphatidylinositol-4,5-
bisphosphate (PI(4,5)P2) to generate phosphatidylinosi-
tol-3,4,5-triphosphate (PI(3,4,5)P3), a second messenger
with several downstream effectors [22]. This lipid-kinase
activity is countered by the phosphatase activity of
PTEN and SHIP1/2, which dampens the effect of class
Ia PI3Ks by hydrolyzing PI(3,4,5)P3 to PI(4,5)P2 and
PI(3,4)P2, respectively. PI3K signaling is crucial to many
aspects of cell growth and survival. Dysregulation of this
signaling pathway by genetic aberrations such as muta-
tion, amplification, and rearrangement is frequently ob-
served in human cancer [22]. Indeed, the loss-of-function
mutation of PTEN and the gain-of-function mutation of
class Ia PI3Ks are observed in both sporadic tumors and
those that arise as a result of predisposition syndromes.
Theoretically, such tumors could be treated by inhibition
of PI3K signaling. In fact, small molecules that directly or
indirectly modulate PI3K signaling have been actively pur-
sued as potential cancer therapies, and some of the inhib-
itors (including some mTOR inhibitors) are currently in clin-
ical trials [23, 24]. Additional molecular entities that target
these pathways could be useful as tools by which to gain
a better understanding of the signaling pathways or as
therapeutics for treating relevant diseases.
We developed an assay for high-throughput identifica-
tion of small molecules modulating the posttranslational
modification status of the 40S ribosomal protein S6,
a downstream effector of mTOR signaling. Compared
with in vitro biochemical assays that measure the activity
of specific protein targets, this cell-based assay can be
used without bias to identify small-molecule regulators
affecting proteins in the pathway without prior knowledge
of their function.
Using this cell-based assay, quinostatin was identified
as a potent inhibitor of S6 phosphorylation. Differential
stimulation of the PI3K/Akt or MAPK pathways showed
that the former was the major regulator of signaling to
S6. Quinostatin phenocopied wortmannin in terms of its
effect on S6 phosphorylation. Through structure-activityer Ltd All rights reserved
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Kinase Inhibitor through Cell-Based ScreeningFigure 4. Quinostatin Targets the Catalytic Subunit of PI3K
(A) Preparation of the affinity resin.
(B) Affinity-purified proteins were separated by SDS/PAGE and visualized by silver staining. The staining of an 85 kD band was sensitive to quinos-
tatin treatment.
(C) Immunoblotting showed that the 85 kD band was reactive toward p85 antibody. This band disappeared when affinity chromatography was
performed in the presence of quinostatin or LY294002. Immunoblotting with p110 antibody showed that p110 was also affinity purified in a manner
that was sensitive to quinostatin or LY294002 treatment. QS, quinostatin; LY, LY294002.
(D) Immunoblotting showed that a recombinant p110 was pulled down from a solution of the purified protein by the affinity resin.
(E) In vitro kinase assays showed that quinostatin dose-dependently inhibited the lipid-kinase activities of the recombinant p85a/p110a and p110g
proteins. Data presented are means of three independent experiments with standard errors.relationship studies, we identified a permissive site for
quinostatin immobilization. The corresponding affinity
resin was synthesized and used to purify quinostatin-
interacting proteins. Both the catalytic and regulatory
subunits of the class Ia PI3Ks were affinity purified. The
binding between quinostatin and a recombinant class Ia
PI3K (p85a/p110a) was independently verified by surfaceChemistry & Biology 14, 3plasma resonance. Quinostatin was shown to inhibit the
lipid-kinase activity of the recombinant PI3K. In addition,
it also inhibited the lipid-kinase activity of p110g, an iso-
form of p110a. Since no regulatory subunit was involved
in the latter case, this result suggested that quinostatin
targeted the catalytic subunit of the PI3Ks. The sensitivity
of the affinity purification of p85/p110 to the presence of71–377, April 2007 ª2007 Elsevier Ltd All rights reserved 375
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being the direct target of quinostatin. This targeting was
further corroborated by the selective binding of recombi-
nant p110g with the quinostatin affinity reagent. While
the p110 protein might have been purified through its di-
rect interaction with the immobilized quinostatin, the p85
proteins were copurified in the form of functional hetero-
dimers. A thorough profiling would be required to deter-
mine the selectivity of quinostatin against other kinases.
However, the data we obtained suggest that quinostatin
did not, in cells, target some of the protein kinases relevant
to mTOR signaling, such as those involved in relaying PMA
stimulation through the MAPK signaling pathway. Thus,
quinostatin represents a new, to our knowledge, chemo-
type for the selective inhibition of PI3K. In light of a recent
report of unexpected synergistic effects of kinase inhibi-
tors with multiple targets [25], it will be useful to profile
quinostatin against the whole kinome in the future.
SIGNIFICANCE
Using the posttranslational modification status of the
40S ribosomal S6protein as the readout,wedeveloped
a cellular assay for unbiased, high-throughput identifi-
cation of small-molecule modulators of mTOR signal-
ing. Quinostatin was identified as an antagonist of
mTOR signaling. Its molecular target was found to be
the catalytic subunit of the class Ia PI3Ks. The molec-
ular scaffold represented by quinostatin constitutes
a new, to our knowledge, chemotype by which thera-
peutically relevant kinase inhibitorsmaybedeveloped.
EXPERIMENTAL PROCEDURES
Materials
All cell culture reagents and the silver staining kit were purchased from
GIBCO/Invitrogen. Wortmannin, LY294002, phosphatidylinosotol, and
the recombinant p110g were purchased from Sigma. Quinostatin can
be purchased from ChemDiv (catalog number: CDL C768-0445). In-
house-synthesized and ChemDiv compound libraries were used in
the screening. The recombinant p85a/p110a protein and p85 antibody
were purchased from Upstate. Other antibodies were purchased from
Cell Signaling Technology. AffiGel-10 was purchased from BioRad.
The EDTA-free protease inhibitor cocktail was purchased from Roche.
The CellTiter-Glo luminescent cell viability assay kit was purchased
from Promega.
Screening of Small-Molecule Libraries
A549 cells were seeded in 384-well assay plates at a density of
4,000 cells/well in 50 ml complete growth media (DMEM plus 10%
FBS) and were incubated overnight. Compounds in DMSO (100 nl,
5 mg/ml) were robotically pinned into the media. The cells were cul-
tured for another 5 hr and fixed with 4% formaldehyde in PBS. Immu-
nodetection of S6 phosphorylation, with a phospho-S6 (serine235/
236) primary antibody and an HRP-conjugated secondary antibody,
was carried out by following a protocol similar to that reported
previously [15].
Affinity Chromatography
Affinity chromatography was performed as described by Wan et al. [26]
with some modifications. MCF7 cells were lysed with a modified RIPA
buffer (50 mM Tris-HCl [pH 7.4], 1% NP40, 250 mM NaCl, 1 mM EDTA,
1 mM NaF, 1 mM Na3VO4, and supplemented with an EDTA-free pro-376 Chemistry & Biology 14, 371–377, April 2007 ª2007 Elsevtease inhibitor cocktail) at 4C for 10 min, and the cell lysate was
cleared by centrifugation. The cleared lysate (1 ml) was tumbled with
the affinity resin (30 ml) at 4C for 2 hr. The suspension was centrifuged,
and the supernatant was discarded. The resin was washed with RIPA
buffer (1 ml) four times. After the final wash, the supernatant was
removed, and SDS sample buffer (30 ml) was added to the resin. The
affinity-purified proteins were heat denatured and separated by
SDS-PAGE. The proteins were visualized by silver staining following
manufacturer’s protocol.
Lipid-Kinase Assay
A reaction mixture containing the recombinant p85a/p110a (or p110g)
protein, quinostatin (in 1 ml DMSO), and phosphatidylinositol (20 mg,
suspended by sonification) in the kinase reaction buffer (45 ml,
120 mM HEPES [pH 7.5], 10 mM MgCl2) was treated with a solution
of ATP (100 mM, 5 ml) containing g-32P-ATP (10 mCi) in the same kinase
reaction buffer. The reaction mixture was incubated at room tempera-
ture for 20 min before the reaction was quenched with 1 N HCl (100 ml).
The resulting mixture was extracted with CHCl3:CH3OH (1:1, 160 ml).
The organic phase was separated and allowed to dry. The residue
was taken into CHCl3 (20 ml) and spotted onto a TLC plate. The plate
was developed in a boric acid developing buffer [27] and then dried.
It was exposed to a film, and the image was quantitated.
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